Nutrition Business Journal

Natures Way, Enzymatic Therapy Merge Sales Teams



The integration of Enzymatic Therapy (ET) and Nature’s Way continued this week with the companies’ announcement that they were merging their sales teams. The move follows the October 2008 acquisition of ET by Germany-based Dr. Willmar Schwabe Pharmaceuticals, which owns Nature’s Way. The newly combined specialty retail field sales team will service the natural health food channel, including independent, regional and national health food stores.

"This integration promises broader and accelerated distribution of two well-known and trusted consumer brands in the natural products industry," Vice President of Sales Karl Lifferth said in a statement, noting that Acidophilus Pearls, Umcka, Alive, Primadophilus, Remifemin and Whole Body Cleanse are some of the most popular brands provided by the two companies. "Our shared focus is to offer these favorites as well as new clinically proven natural products for the well-being of consumers everywhere."

At the time of the ET purchase, Randy Rose, who is now the president and CEO of the combined ET and Nature’s Way, told Nutrition Business Journal the deal was significant because the two companies’ product portfolios were complementary and there was little overlap in sales channel focus. “If you look at the product lineups from Enzymatic Therapy and Nature's Way, we operate in different market segments,” Rose said. “Historically, Nature's Way has been very strong in single herbs, herbal extracts and a few really unique value-added products. Enzymatic Therapy has not been in the singles business at all. It has been in multiple-component natural medicines. That is why I think there's a beautiful fit from a product standpoint.”

Related NBJ links:
2008 Deals of the Year

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.